You have been on the top dose for months now. The scale moved steadily on the way up the dose ladder and then it stopped. Each month a telehealth clinician spends 15 minutes with you, renews the prescription and ends the visit. When you asked what came next, you heard that there is nothing else to try. When you asked about blood work, you were told, “Your labs are fine.”

If you have stopped losing on the top GLP-1 dose, the question you are typing is a fair one. Do you need labs when your doctor says yours are fine? The plain answer is yes, as long as someone reads them with you and acts on what they show. A plateau at the top dose is a clinical finding with possible reasons. Some of those reasons show in blood and some do not. When a GLP-1 stops working, GoodLife Health tests to find the reason before anyone raises a dose or decides the options are exhausted.

This piece is written for the patient whose prescription renews every month while the weight holds still. It covers what the word “fine” may leave out, what a fuller panel reads, what the GoodLife Health membership costs and who should not buy it.

Key Takeaways
  • A plateau at the top dose calls for current labs before any new decision.
  • “Fine” means inside a population range on whatever was drawn, so ask what was drawn and when.
  • GoodLife Health reads nine biomarkers every 90 days, among them Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4, Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP.
  • Medication is branded and FDA-approved only, sent to your pharmacy at its own price with nothing taken on it.
  • The membership is $299 a month. The $598 hold is released if a clinician cannot accept you and is charged, non-refundable, once one does.
  • No weight loss, coverage or particular drug is promised.

A 15-minute sign-off and nothing left to try

The monthly visit has a shape you could recite by now. You report your weight and say whether the nausea is better or worse. The clinician confirms that nothing alarming has happened, renews the prescription and wishes you well. The whole exchange fits inside 15 minutes because it was designed to fit there. Its purpose is to keep a prescription current.

For a while that was enough. Each step up the dose brought a new loss, so the monthly check felt like progress. Then you reached the top dose. The steps ran out and the loss ran out with them. You have eaten less and walked more for weeks without a change on the scale. Nobody in those visits has asked you about it in any detail.

So you asked the obvious question. The answer was kind and it was final. You are on the maximum, the clinician said, with nothing else to try. When you raised the idea of blood work, the reply closed that door too. Your labs, you heard again, are fine.

You may not know which labs those were. They may have been drawn before you started the medication. A different doctor may have ordered them a year ago for a different reason. This service may never have drawn any at all. The word “fine” arrived without a date or a list attached.

Meanwhile, the medication bill arrives every month for a drug that has stopped doing what it did. The worry underneath is reasonable. If the top dose has stopped working and nothing else exists, you may have reached the end of what medicine can do for your weight.

It is worth saying plainly that you did nothing wrong. You took the medication as prescribed and climbed the doses as instructed. A stall at the top is a clinical question. It deserves a clinician's answer with your numbers on the table.

What “fine” covers and what a plateau can mean

“Fine” is a word about a range. A result is called normal when it falls inside the reference range printed on the report. That range describes a population. You are one person with numbers that have a history. The history is where a plateau can begin to make sense.

The word also covers only what was drawn. A basic panel can come back clean while markers that bear on a stalled GLP-1 were never ordered. Fasting insulin is the clearest example. It can be measured before glucose turns abnormal, so a normal glucose on its own does not answer the question fasting insulin asks. GoodLife Health reads Fasting Insulin and Hemoglobin A1c (HbA1c) together for that reason.

Our definitive guide to cardiometabolic optimization describes the body as one system. In its account, insulin resistance drives weight gain, visceral fat disrupts hormones and disrupted hormones stall metabolism. The guide also names hormonal health as the axis most weight-loss platforms skip and a reason so many protocols stall. Thyroid function belongs to the same system. That is why TSH With Reflex To Free T4 is read every quarter beside Fasting Insulin and Hemoglobin A1c (HbA1c).

It helps to remember what the trials reported. In STEP 1, semaglutide 2.4mg produced roughly 15% average body-weight loss over 68 weeks. In SURMOUNT-1, tirzepatide produced up to about 21% over 72 weeks. Those are averages from trial populations. An average includes people who lost more and people who lost less. Where your own plateau sits against those figures is something only your history and your results can begin to explain.

There is also the question of what a monthly sign-off is built to do. When a service earns on the prescription, the renewal is the product. The visit exists to keep it moving. That design does not make anyone careless. It does mean that a question like yours, which needs testing and time, has no natural home in a 15-minute renewal. “Nothing else to try” can mean nothing else that fits inside the visit.

Some humility belongs here too. Some of what sits behind a stall will never show in blood. A clinician has to ask about the rest in conversation, with time to listen. We do not know, before the panel, why your weight stopped. We will not tell you the panel holds the whole answer. What we will say is that deciding without it is guessing. The guide describes the quarterly re-audit as what turns a prescription from a guess into a feedback loop.

Clinical note

At the top dose, the next clinical decision should rest on current results. Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4 and Apolipoprotein B (ApoB) are read together before the plan changes.

A monthly refill on a stalled dose is a decision to change nothing, made without looking.

What the membership does when the dose cannot go up

GoodLife Health is clinician-led precision direct primary care for cardiometabolic optimization. At a GLP-1 plateau, it finds the reason before raising the dose. At the top dose, the same rule applies before anyone calls the options exhausted. Labs come before the prescription and every quarter after.

The first step is the panel. The membership includes four cardiometabolic lab panels a year, drawn every 90 days. Each panel reads nine biomarkers, among them Fasting Insulin, Hemoglobin A1c (HbA1c), TSH With Reflex To Free T4, Apolipoprotein B (ApoB), Lipoprotein (A) and Hs-CRP. Every result is in your hands. A clinician reads them with you on a video visit and builds the plan from what they show. Our piece on what a direct primary care visit actually looks like describes how that differs from a renewal. Between visits, you message the care team when something changes. The clinician stays with you as the markers move, so each panel is read against the one before it.

What follows depends on the results and on the clinician's judgment. Any FDA-approved medication a clinician judges indicated can be prescribed to your pharmacy. That can be a different branded GLP-1 such as Wegovy, Zepbound, Mounjaro or Ozempic. It can be an oral option where one is indicated. It can be thyroid medication or hormone therapy where the results call for it. It can also be the medication you already take at the dose you already take, kept on purpose with numbers behind the decision. The clinician decides with you. The membership promises none of these in advance.

If your current prescription is a compounded GLP-1, the membership will not continue it. GoodLife Health prescribes branded, FDA-approved medication only. The FDA has published its concerns about unapproved GLP-1 drugs used for weight loss. A clinician's license carries the responsibility for what is prescribed. A move from compounded to branded medication is a labs-first transfer. The clinician reviews your current dose and decides with you how to proceed.

Medication is unbundled from the fee. It is prescribed, when clinically indicated, to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. The fee is the same whatever medication is indicated and whatever the dose. There is no molecule upcharge and no dose upcharge.

The prices themselves are now public, which is a recent change in how branded medication is bought. As published by the manufacturers in September 2026, LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose. NovoCare lists Wegovy pens at $349 a month, with $199 a month for the first two fills as an introductory offer for new patients through December 2026. The Wegovy pill starts from $149 a month at lower doses. Whether insurance covers a medication is between you, your plan and the pharmacy. Prior authorization is the pharmacy's process. GoodLife Health does not run it or promise its outcome.

You may ask why you would pay a membership on top of a medication that already costs this much. The medication is the expensive part. The membership pays for the decision about it. For $299 a month, you get the panel, the clinician who reads it and the care between visits. That fee does not rise if the clinician changes your drug or your dose. Neither the drug nor the dose earns us anything, so the plan can follow your results.

If you already have a prescriber, you already have someone who can renew. A stall asks for someone who can test, read the results and change course. This market runs from the $99-a-month compounded app to the $20,000-a-year concierge practice. GoodLife Health sits between them and says so. What matters at your plateau is what each model is paid for. We are paid for the care and take nothing on the prescription.

The membership in numbers
$299
a month, month to month from month three
$598
held for months one and two, released if you are not accepted, charged and non-refundable once you are
4
cardiometabolic lab panels a year
9
biomarkers on each panel
50
states where the clinicians are licensed

The membership also has limits worth stating. It does not promise that you will start losing again. It pairs with your insurance for catastrophic coverage and does not replace it. It does not promise that any medication will be covered. Not everyone is accepted. The path is the eligibility check, the intake, the checkout and then a clinician's review.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

What to do this week whether or not you join

Start by asking your prescriber for copies of every lab result on file, with the date each was drawn. Read the list of tests before you read the values. If fasting insulin, A1C, a thyroid test, ApoB and Lp(a) are missing, you know what “fine” did not cover. If the results predate your first dose, you know they describe someone who had not yet started the medication.

Next, write down your dose history. Note the date of each step up, the date the weight stopped moving and any side effect that nobody has addressed. A clinician anywhere will make a better decision with that page in front of them.

Then ask your current prescriber two direct questions. What would you test if the stall continues? What would you change if the tests came back abnormal? The answers will tell you whether the care you have can take this further. They are worth having whether you stay or move.

Finally, check what your own pharmacy charges for the medication you take. Compare it with the manufacturers' published prices above. Knowing your medication cost apart from your care cost makes every later decision clearer.

Who this is not for

This membership is not for the patient who wants the cheapest monthly refill and nothing more. If a renewal is all you want, a $99 app is built for it. The membership is not for anyone who wants compounded medication, a guarantee of weight loss or a promise that insurance will pay for a drug. It is not for someone unwilling to have blood drawn every 90 days, because the panel is the point of the model. It is not for anyone living outside the United States. If any of those describes you, keep your money and use the steps above.

The membership is $299 a month. At sign-up, $598 is held on your card for the first two months. If the clinician cannot accept you into care, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, it is month to month. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee buys the quarterly panel with every result in your hands, a clinician who stays, video visits and messages with the care team between visits. Medication goes to the pharmacy you choose at its price and we take nothing on it. In return, you get the diagnosis a 15-minute renewal never produced, your markers followed over time and an end to the sign-off visit. The model is different because it tests first, treats second and sells neither the drug nor the dose. If you are on the top dose today with nowhere left to climb, the next decision deserves your numbers. The panel is how you get them.

Related Reading

References

  1. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
  2. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
  3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
  5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/